In the context of introducing new products around the world, it is important to understand the relative attractiveness of various countries in terms of maximum penetration potential and diffusion speed. In this paper, we examine these market characteristics for a new category of prescription drugs in both developing and developed countries. Using data from fifteen countries, and a logistic specification in the Hierarchical Bayesian framework, we report the differences in diffusion speed and maximum penetration potential between developing and developed nations. Our methodology accounts for the limited number of data observations as well as serial correlation and endogeneity problems that arise in the analysis. The principal findings include: (i) Compared to developed countries, developing nations tend to have lower diffusion speeds and maximum penetration levels; (ii) Laggard developed countries have higher speeds. However, laggard developing countries do not have higher diffusion speeds; (iii) Per capita expenditures on healthcare have a positive effect on diffusion speed (particularly for developed countries), while higher prices tend to decrease diffusion speed. The paper concludes by identifying useful avenues for additional research.
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Introduction
Many developing nations, with their relatively large populations, have attractive potential buyer segments that may exceed the size of an entire developed nation's market. In an era of less prevalent trade barriers, more common consumer preferences across the globe, and market saturation in developed nations, there is an increasing need to understand the market characteristics of these developing nations. In particular, as firms introduce their products and services across countries, it is important to assess the relative attractiveness of various nations in terms of their market potential, the likely speed of diffusion and the impact of marketing mix elements (such as prices) on that speed. These factors have important strategic value and in this paper we explore such market characteristics in both developing and developed nations. In the context of the diffusion of a new subcategory of pharmaceutical drugs, we examine the diffusion speed, maximum penetration potential, and the effects of prices and per capita health care expenditures in fifteen countries (ordered first by entry date and then alphabetically): Belgium, South Africa, USA, Spain, Italy, Mexico, Canada, UK, France, Netherlands, Brazil, Colombia, Venezuela, Australia, and Portugal.
Over the last three decades, the marketing literature on new product diffusion has focused mainly on durable products, in varying subsets of industrialized countries (c.f. Mahajan, Muller and Bass 1990; Dekimpe, Parker and Sarvary 2000a) . In recent years, there has been an increasing effort to study the diffusion process in the other parts of the world. Our study adds to this growing literature as follows.
First, by studying diffusion of new drugs, we aim to add to the existing empirical findings in other product categories; collectively, these can help develop empirical generalizations. For instance, extant research reports that developed nations tend to have significantly higher maximum penetration levels than developing nations (see e.g., Talukdar, Sudhir and Ainslie 2002) . Similarly, a consistent finding in the literature is that laggard countries (i.e., where the product is introduced later) tend to have faster diffusion patterns (Dekimpe, Parker and Sarvary 2000a) . We explore whether these findings hold in the context of our data.
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Our analysis focuses on developing and developed nations. Pharmaceutical markets in these countries exhibit important differences that can lead to differences in diffusion speed and penetration potentials. As noted earlier, developing countries tend to have much larger populations than developed ones, and are thus likely to have higher penetration potentials. By definition, developing countries also tend to be less economically advanced. The level of economic development of a country, along with the resources devoted to healthcare, has a significant influence on its health system, particularly on the supply and quality of health resources. Lower economic development often implies a less educated and more rural population that has a lower demand for scientific medicine. Further, the level of heath care provision among the population is also lower. For example, the more developed countries spend around 5 to 10 percent of their GDP on health care, compared to 2 to 5 percent in most developing countries. We expect such factors to result in significantly lower diffusion speeds in developing countries.
Next, prices of the drug can affect the demand and speed of diffusion. In the US, for instance, organizations such as HMOs in the market determine the approved list of drugs to be prescribed by affiliated doctors ("formularies") based on drug prices. In Europe, governments maintain "positive"
and "negative" lists, to reflect drugs that will and will not be reimbursed. Some countries have a tiered system, in which some drugs will be reimbursed at higher rates than others. In addition, both developing and developed nations have large uninsured population segments that are fully liable for the cost of the drug. We thus expect higher drug prices to lower the speed of diffusion within a country, all other factors held equal. Furthermore, we expect developing countries, with their lower income populations, to have higher sensitivity to prices than developed countries. In our diffusion framework, we capture these differences by allowing aggregate per capita health care expenditures and drug prices to affect the diffusion speed differently in developing and developed countries.
It is worth noting that most diffusion studies do not examine the impact of marketing mix elements, such as prices, on the diffusion process. Recent literature (c.f. Van den Bulte and Lilien 1997) notes that not accounting for the effect of marketing mix elements may result in exaggerated estimates of the contagion parameter. For example, if there is a systematic decline in prices that leads to increased adoption, and prices are not included in the model, the increased adoption is likely to be attributed to the diffusion parameter. We take a step towards bridging this gap in the literature and explicitly incorporate the impact of prices on the diffusion process.
Finally, left-censoring -that is, the problem of data not including observations from the inception of the category in each country -is often a concern in cross-national comparisons. In such instances, observations at a given point in time may be capturing a different stage in each country's diffusion curve; therefore across-country comparisons could be biased if each country's temporal stage in the diffusion curve is not controlled for (Dekimpe, Parker and Sarvary 2000a) . This issue is mitigated to a great extent in our analysis since we obtained data from the inception of the category in each country included in the study.
The diffusion framework we employ is a discrete-time version of the logistic model presented in Van den Bulte (2000) . The logistic model is attractive for our purposes since it directly addresses the issue of measuring diffusion speed and allows for a straightforward comparison of markets in a cross-national setting. We adopt a Hierarchical Bayes (HB) approach to estimate the parameters of the model. A significant advantage of the HB approach in the diffusion context is that it enables the pooling of information across countries to develop more precise estimates of model parameters. In contrast, standard estimators of the diffusion parameters would need far more data to obtain reliable estimates. In many real world settings, where managers seek forecasts of sales when products have just been introduced, such data may not be available. HB estimators are very useful in such sparsedata situations and researchers have been calling for more work with these methods (e.g., Lenk and Rao 1990 , Putsis and Srinivasan 2000 , Rossi and Allenby 2003 . In addition, the HB approach allows us to obtain posterior estimates of diffusion parameters specific to each country in a statistically consistent manner that takes into account the uncertainty associated with the model and the available data.
In estimating the model, like many past diffusion studies, we find evidence for significant persistence (or serial correlation) in the unobserved shocks to diffusion. The persistence in the diffusion shocks introduces an errors-in-variables or endogeneity problem since lagged cumulative sales, included as a covariate in the estimation equation, contains unobserved shocks from previous time periods that are correlated with current period shocks. If uncorrected, this could lead to inconsistent estimates. We implement an instrumental variables procedure to correct for this endogeneity. The proposed instrumental variables procedure is embedded within the HB framework and the model is estimated using the Gibbs sampler.
Our main empirical findings include: (i) Compared to developed countries, developing nations tend to have lower diffusion speeds and maximum penetration levels; (ii) Laggard developed countries have higher speeds. However, laggard developing countries do not have higher diffusion speeds; (iii) Per capita expenditures on healthcare have a positive effect on diffusion speed (particularly for developed nations). Higher prices tend to decrease diffusion speed (i.e., estimates of the price coefficients are negative for all countries); however, except for Brazil, the coefficients are not significant statistically. These results add to our current understanding of the variation in diffusion speed across countries, especially in the context of comparing developed and developing nations.
The rest of this paper is organized as follows. The next section provides a review of the relevant literature. The subsequent two sections discuss our model, the data and estimation issues.
Section five presents the results, and the penultimate section explores the underlying reasons for the differences between the two types of nations. The final section concludes the paper with suggestions for further research.
Relevant Literature
Here we focus on two streams of literature: (1) The recent wave of research on the marketing and diffusion of pharmaceutical drugs; and, (2) the research that examines developing nations and compares them with developed nations. Each of these is discussed below.
Recent years have seen dramatic increments in marketing spending by pharmaceutical companies; for instance, direct to consumer advertising (DTC) spending increased from less than a billion in 1996 to more than 2.5 billion in 2000 and is expected to grow even more in the coming years. The increased spending has drawn attention from practitioners and academics on analyzing the effects on demand and the return on investment (ROI) from such marketing activities. Research that has focused on studying aggregate pharmaceutical demand includes Berndt et al. (1997) and Rizzo (1999) Other recent studies on pharmaceuticals use individual-physician-level data to understand prescription behavior of physicians. For example, Kamakura and Kossar (1998) examine the adoption/timing of physician's drug prescription decisions; Manchanda, Rossi and Chintagunta (2003) model physician prescription behavior within a framework that allows response parameters to be affected by the process by which detailing is set across physicians. These studies, too, are not explicitly concerned with understanding the diffusion of the drug within and across countries.
Past research that focused on the diffusion of pharmaceuticals includes Hahn, Park, Krishnamurthi and Zoltners (HPKZ) (1994) and the papers cited therein. Since word of mouth has long been known to be an important influence on pharmaceutical sales (see e.g., Coleman, Katz and Menzel 1966) , these researchers have argued that the diffusion framework is appropriate to study the sales growth of pharmaceutical drugs. HPKZ, for instance, expand the diffusion framework to account for repeat purchases and estimate a repeat rate parameter for 21 new pharmaceutical 6 product categories. Interestingly, only about eight among the 21 categories studied had a repeat rate that was significantly different from zero at the 0.05 level; the maximum of these rates was 25%, while the lowest was 7.7% (see Table 2 , the panel on HPKZ1, p. 233). Other researchers who examined the sales growth of pharmaceuticals, however, do not explicitly account for repeat rates.
For example, Berndt, Pindyck and Azoulay (1999) , who study anti-ulcer drugs in the US, use the Bass (1969) model to characterize network effects in drug diffusion. Analogously, though we employ the diffusion framework in our analysis, repeat purchases are not explicitly taken into account. In light of HPKZ's findings, our analysis can be viewed as being applicable to categories with very low repeat rates; for other categories, the analysis may be seen as an upper-bound benchmark. 2
As noted in the introduction, most existing cross-national diffusion studies focus on developed nations. In contrast, we examine both developing and developed nations. In addition, our specification and analysis revolve around diffusion speed -since one of our goals is to compare these speeds across national markets. This focus distinguishes our study from both Talukdar et al. (2002) and Dekimpe et al. (2000b) ; while those studies explicitly account for non-industrialized nations, neither is explicitly concerned with diffusion speed.
Model
The new product growth model that we employ follows the logistic specification in Van den Bulte (2000) . The model specifies the growth rate of sales for a new product in country i at time t, as a function of cumulative sales at the beginning of period t, ( ) i t X , and the population ( )
where, i α represents the maximum penetration level, and indicates that the maximum possible sales in each period is linearly related to the population in the country. We consider the discrete-time analog to the above equation. 3 Denoting the realized sales in each period (
as it x , we can write the following discrete-time version of the model in (1.1):
The logistic formulation in (1.2) is useful for studying diffusion speed because of the following reason:
Begin with a simple definition of diffusion speed, stated as the amount of time required to move from one level of market penetration (say, p1%) to another (say, p2%). As noted in Van den Bulte (2000) , in the continuous time analog of the logistic model, this time difference equals
where, it ε represents deviations from the model-predicted growth rate, and is assumed to be a mean zero error term, distributed standard normal with variance 2 σ . As seen from (2), the appealing property of the logistic framework is that the diffusion speed i θ is linearly related to the empirical instantaneous growth rate, it y . This makes the formulation appealing for studying diffusion speed.
Given that cumulative variables are regressors in (2), a priori, we can expect some serial correlations in the residuals. We allow for first order auto-correlation in υ is a mean-zero white noise term assumed to be orthogonal to all
, where ( ) i F t is the cumulative distribution function of sales, we see that the continuous differential equation in (1.1), is equivalently
, the solution to which is a logistic function, ( (Fisher and Pry, 1971) . Essentially, our model focuses on the imitation process; this is reasonable since previous research (e.g., Coleman et al 1966) suggests that word-of-mouth is an important influence in pharmaceutical sales growth. (2). In essence, the estimation equation (2) becomes a canonical linear model with a lagged dependant variable and serially correlated errors, which gives inconsistent estimates unless the endogeneity is controlled for (e.g., see Johnston and Dinardo 1997) . Note that this problem is not specific to the framework that we use: the endogeneity issue is a problem for all diffusion studies that employ a linearized estimation equation similar to (2), when serial correlation is present in the residuals. 5 The solution to the endogeneity problem is to find a set of exogenous instruments it Z that are correlated with the endogenous variable , 1 i t X − , but are uncorrelated with the residuals it ε .
Intuitively, we should only use variation in , 1 i t X − that is "explained" by the exogenous variables it Z for estimation. All other unexplained variation in , 1 i t X − is possibly correlated with it ε and should be ignored. The use of instrumental variables enables us to do precisely this, and we discuss the details of the procedure later in the estimation section.
Recall that the main goal of our analysis is to understand differences in the diffusion speed (and thus indirectly, in the growth rate) across countries. Furthermore, we wish to study the effect of 4 In our estimation section, we report evidence for such serial correlation in the residuals. A regression of the residuals from our "base model" in section 5 on lagged values, εit = ρεi,t-1 + υit, gave an estimate of 0.2715 for ρ with a t-statistic of 12.3, indicating significant persistence in the residuals. Running the Durbin (1970) h-test, we rejected the null of no first order autocorrelations in the residuals. 5 For instance, using OLS for estimating the linearized version of the Bass diffusion model, xt = a + b Xt + cXt 2 + εt, would result in biased and inconsistent estimates for a, b and c, if there exists serial correlation in εt.
both time-invariant variables (e.g. country characteristics) and time-varying variables (e.g. prices) on the diffusion speed. We therefore allow i θ in (2) to be influenced by both time-varying and timeinvariant control variables. Since by construction, i i i γ θ α = − , this implies that we need to also allow i γ to be a function of the same variables. 6 Formally, we specify:
where the W-s are time-invariant covariates, the D-s are time varying covariates, and a t-subscript has been added to θ and γ to reflect the effect of the time-varying variables. Note that with these parameterizations, the estimation equation (2) 
We allow all the parameters in (4) to vary across countries according to the following hierarchical set-up. In the first stage of the hierarchy, we specify:
where, β µ is the mean of the i β -s, and Ω is the precision matrix for the distribution of the i β -s around this mean. The uncertainty about the parameters of the above distribution is specified in the second stage of the hierarchy as:
Finally, the priors for the residual standard deviation and the auto-correlation parameter are specified as:
We adopt a Bayesian method to estimating the hierarchical model above for two reasons: (i) we seek direct inference about the country-specific parameters [Tables 1 and Figure 1 here] Table 1 provides the introduction timing of the category in the different markets. The time period of the data includes the initial launch of the drugs in each country, and the observations begin with the introduction of the category. The availability of data from the inception of the category mitigates the left censoring problem common to many past diffusion studies. Even with this controlled for, there could still be a censoring problem to the extent that we do not observe factors such as newspaper articles and trade-press reports about the drug that build demand prior to entry in countries where the drug is introduced later (we thank an anonymous reviewer for pointing this out). A variable representing the time since introduction in the lead country, included to control for such effects, turned out to be insignificant in all empirical specifications we considered. Hence, using these criteria, this issue does not seem to be very important for SSRI antidepressant drugs.
Nevertheless, the availability of actual data on these factors could enable us to better calibrate and understand the influence of these effects on diffusion.
Descriptive statistics of the data are provided in Table 2 . In each country, the price variable captures the average selling price charged by the manufacturer (and is not the retail price) expressed in equivalent US dollars. The sales units are in terms of kilograms of the drug. In addition to prices, we also use per capita expenditures on health care to explain differences in diffusion speed across countries. The per capita expenditures variable is expressed in constant 1989 dollars and is obtained from the Global Market Information Database provided by Euromonitor.
[ Table 2 here]
To obtain a perspective on this category of drugs, note that the estimated shares of the SSRIs among all antidepressants vary from country to country; for example, in the USA the share has been around 33% (estimated by averaging quarterly shares over a ten year period starting 1988; see Chintagunta and Desiraju 2002) , while in Italy it is about 9%, and in France and the UK it is around 20%. This limited penetration is primarily due to the availability of alternative non-SSRI drugs (such as tricyclics and monoamine oxidase inhibitors) for treating depression. While SSRI-s are as a class, often the first-choice for treating depression, they do also have several side effects such as symptoms of gastrointestinal upset, sleep impairment, impaired libido, and anorgamia (see e.g., Morrison 1999 ) that sometimes prevent their use. Further, in several countries, there is a belief that non-allopathic medications are more effective in treating depression and related disorders. For these reasons, the SSRI-s did not have relatively high penetration rates for the duration of our data.
With this brief background on the market for SSRI drugs we now turn to the procedure for estimating the model.
Estimation
We conduct the estimation in two steps. We first use an instrumental variables procedure to obtain a predicted value for the endogenous variable , 1 it i t x X − in (2) which uses only variation in
is explained by a set of exogenous instruments. We then use the predicted values as data, and estimate the entire hierarchical diffusion system (5)-(9) using a Bayesian procedure. 7 Further, to assess the robustness of the analysis, we drop the last observation for each country from the data and re-estimate the model parameters (the results of this analysis are available from the authors on request) -this generated little changes to the reported results for the full data set and gives us confidence in the robustness of our results. Further details of the instrumental variables procedure and the Gibbs sampler used for estimation are presented in the appendix.
As a significant byproduct of the Gibbs sampling procedure, we obtain the distribution of the posterior coefficients ( i β ) for each country. With access to the full data on diffusion, we can infer about the parameter specific to each country based on our knowledge of the marginal distribution of i β and the value of the country-specific variables. To update our inferences to this full data, we must simply compute the posterior distribution of
it X W D y x and the information in the entire set of countries. This is given automatically by the posterior distributions constructed from the Gibbs sampler run with all the countries in the dataset. Once the country-specific parameter vector i β is obtained, it is straightforward to obtain estimates of other quantities of interest (e.g. mean diffusion speed and maximum penetration potential) for that country.
Results
Three sets of results are presented here, each in a separate sub-section. The first sub-section focuses on exploratory regressions; the second on the mean parameters of the full model specified in (2)- (9); and the third sub-section presents the country-specific parameter estimates which address the principal research questions of our paper.
Exploratory regressions
The results from regressions of sales on lagged cumulative sales and other explanatory variables are presented in Table 3 .1. The first regression -the "base model" -has per capita health expenditures, lagged cumulative sales per population, and prices as variables; the second has two additional controls for competitive conditions in the market, viz., the number of firms in the market, and interactions of the number of firms with prices; the third adds interactions of prices and per capita health expenditures with lagged cumulative sales per population. The data are pooled across all countries and time periods in all the regressions. Referring to Table 3 .1, we see that all parameters have the expected sign. The effect of per capita expenditures is positive and significant; that of the past installed base (lagged cumulative sales/population) is negative and significant, and the effect of prices is negative but insignificant. Both the competitive variables are insignificant here and also in our subsequent analysis and hence were dropped from the final chosen specification.
We tested for the presence of serial correlation in the residuals using the Breusch-Godfrey
Lagrange-Multiplier (LM) test (Breusch 1978 , Godfrey 1978 Table 3 .1 were similar. Thus, to summarize, we find significant evidence for persistence in the residuals for these data. As noted earlier, this implies that the resulting endogeneity problem cannot be ignored. Finally, White tests rejected heteroscedasticity in the residuals for all specifications.
We now discuss the results after using instruments to control for the endogeneity. Table 3 .2 presents the results from the corresponding regressions to Table 3 .1 when we instrument for the lagged cumulative sales per population variable. As discussed in the appendix, the instrument is constructed as the predicted value from a regression of the endogenous variable 
Posteriors for the mean parameters
We now discuss the estimated posterior coefficients for the full model specified in equations (2)-(9).
Note that these results correspond to a hierarchical linear model with autocorrelated errors, in which predicted values from the instrumental variables regression,
, are used as "data". 9
The full model specification uses two country-specific control variables, viz., prices (which are time varying and correspond to the ikt D variable in equations 3.1 and 3.2) and per-capita health expenditures (which are time-invariant and correspond to the ij W variable in equations 3.1 and 3.2).
Recall that these enter the estimation equation (2) 
Posteriors parameters at the country level
Our main focus is on the country-specific parameters, and we summarize our findings in this subsection. We first discuss the country-specific counterparts of the mean parameters discussed in the previous subsection, and then compare the implied diffusion speeds and maximum penetration levels among the countries in our sample, focusing mainly on the differences between the markets in developing and developed countries. Section 6 presents anecdotal evidence to explain some underlying reasons for our results.
Country-specific parameter estimates
Country-specific effects of heath expenditures on diffusion speed are presented in the first two columns of Table 5 . Among the developed nations with statistically significant coefficients, we find that the Netherlands has the largest impact from health expenditures, while USA and Belgium have the lowest impact; of course, Australia, Canada and Italy have non-significant coefficients, and therefore experience limited impact from these expenditures. Among the developing countries, these expenditures all have the correct sign but are not significant statistically.
From Tables 5, we note that the posterior means for prices all have the correct signs for each of the countries in the sample; the size of the effect, however, varies across countries. From Table 5 , we note that while its coefficient is negative in all the countries, price has a statistically significant impact only in one country (Brazil). This was expected since the mean price effect across all countries was not significant, and suggests that while higher prices tend to reduce diffusion speed, they do not play a significant role for antidepressant medications. The possible substantive reasons underlying this result are discussed in section 6.
Among the developed countries, the main effect of lagged cumulative sales is highest for Netherlands and lowest for Australia, with USA, Italy, Canada, and UK having values in between.
Among the developing countries, the effect is significant only for Colombia. The lagged cumulative sales significantly affects sales growth via an interaction with per capita health expenditures in Spain, France and Portugal. Overall, while all the developed countries experience the diffusion effect from an installed patient base (as captured via lagged cumulative sales), only one developing country experiences this effect.
Country-specific diffusion speeds and penetration levels
We now turn to Table 6 to highlight the mean diffusion speeds and maximum penetration levels at the individual country level. The mean diffusion speed for each country in Table 6 , i θ , represents the mean of the posterior distribution of the average value of it θ (that is the mean of the left-hand side of equation 3.1) computed across all the observations for that country. The maximum penetration potential in Table 6 , i α , is computed as the observations for that country. A significant advantage of the Gibbs sampler is that these can be computed directly by making draws from the stationary distribution of the parameters for each country. Note that the mean diffusion speed and penetration potentials computed as above also reflect the effects of time-varying variables, viz., prices in each country. One could instead report the diffusion speed (and analogously, the maximum penetration potential) without including the effects of time-varying variables. We adopt the former approach, since it allows the diffusion speed to also reflect the variation in sensitivities to prices across countries.
One striking feature of Table 6 is that all the developing countries (except Mexico) have below average diffusion speeds; further, among these countries, diffusion speed does not increase for laggard countries (i.e., where the drugs are introduced later). In contrast, except for Portugal, laggard European countries have higher diffusion speeds than other European countries; a similar pattern holds between Canada and USA -Canada, the later entrant has a higher speed. It is worth noting that the above results for laggard developed countries are consistent with those found in earlier research. However, the pattern for the developing countries is the first we have seen in the literature and suggests that future research should understand this in more detail.
Turning to the maximum penetration potential, i 
Discussion
As noted in the introduction, developing counties are, by definition, economically less advanced than developed nations. Lower economic development, in turn, translates to inadequate infrastructure for delivering health care to the population. Table 7 indicates that developing nations have a relatively smaller number of doctors or hospital beds per capita. With limited health care delivery systems in place through which new drugs can diffuse into the population, penetration potentials and diffusion speeds for these countries are naturally lower.
[Insert Table 7 here]
The lack of comprehensive health care delivery infrastructure in developing countries also implies that only urban populations are likely to contribute to new pharmaceutical product growth. Since urban areas constitute only a fraction of the total national population, diffusion speed and penetration rate tend to be low. Further, restricted communication between urban and rural areas limits the role of the installed base of users in the diffusion process. The predominance of a rural population also implies that laggard developing countries may not experience faster speeds due to a ceiling effect -given that new products are not likely to diffuse through non-urban areas, there is a cap on the incremental (rate of) growth that the laggard countries can achieve. Table 7 also indicates significant variation in the number of women aged between 15 and 49 across countries. Ingram and Scher (1998) observe in their review of epidemiological studies that gender is significantly correlated with depression. More specifically, the lifetime prevalence rates for depression is higher in women (7.0%) than in men (2.2%); these differences occur across a variety of ethnic groups (e.g., African Americans, Hispanic, Caucasian) even when differences in education, income, and occupations are controlled. Other factors such as socioeconomic status are not particularly correlated with these mental disorders. With access to more cross-country data, it is possible that researchers can measure the extent to which these gender ratio differences further explains differences in penetration potentials across countries, after controlling for population size.
Finally, we speculate that low price sensitivity of patients in this category of pharmaceuticals drives our empirical finding that prices do not significantly decrease diffusion speed. However, since we do not have patient-level data, we are unable to explore this issue further.
Here, it is also worth noting that our results were obtained with aggregate country-level data, which does not have information on region-to-region variation in sales and prices within each country. With access to data on sales and prices at a finer level of aggregation -for example, at the city or regional 20 level, we might be able to measure the various effects with greater precision. The availability of such data would be an important advance in further understanding the diffusion process within and across countries.
Overall, developing countries, with a welfare-oriented ideology, have been undertaking major efforts to bring health services to rural people through networks of health centers and extensive training and use of auxiliary personnel. There are currently numerous initiatives to allocate health manpower to rural areas and generally to extend health service coverage. This may be seen as an opportunity for drug companies to invest in these countries to develop the appropriate infrastructure, which will in turn help grow pharmaceutical sales.
Conclusions
For a variety of reasons, developing countries are increasingly becoming economically important.
Both practitioners and academics have an interest in understanding the markets in these countries and in this paper we take a step in that direction. Our empirical analysis reveals some important differences in the diffusion process between developing and developed countries. In line with previous research we find that maximum penetration levels tend to be lower in developing countries;
further, we find that among developed countries, laggard markets -where the product is introduced later -have faster growth rates. We also find that this result does not generalize to the developing countries; there, diffusion speeds tend to be smaller (compared to developed countries) and laggard countries do not have higher growth rates.
We find that cumulative past sales are significant in explaining diffusion speed, particularly in developed nations, implying that the size of the installed base of past adopters is an important factor for drug diffusion. Further, in this product category, we find that even though its impact is relatively small, higher prices tend to reduce diffusion speed. We also find that a macro level covariate, per capita healthcare expenditures has a significant positive effect on diffusion speed, particularly in developed nations.
An area that is worthy of research attention is the impact of other elements of the marketing mix (e.g., detailing in the context of prescription drugs) on new drug diffusion. Inclusion of these marketing mix elements in the analysis may further help explain some of the differences across various national markets. Future research should also explore the role of repeat purchases in pharmaceutical diffusion. We believe our analysis serves as a useful starting point for future researchers, and hope that our effort here will help spark further research in this area. , and are chosen to be non-informative. A diffuse uniform prior is set on ρ over the stationary interval (-1,1).
Draws from the posterior distribution of the parameters are obtained using the Gibbs sampler implemented within the WinBUGS Bayesian analysis software (Spiegelhalter et al. 1995) .
The first 20,000 draws are used as burn-in and the last 10,000 draws are used to generate all posterior parameter estimates and standard deviations. Convergence was assessed using visual inspection of the chains and using the Gelman-Rubin statistic from running parallel chains. Tables 1, 2 and 6, the countries are ordered first by entry date and then alphabetically. Data are pooled across all countries and time-periods. Dependant variable is sales/(lagged cumulative sales) in all regressions. The variables: "Number of firms in market", and "Number of firms in market*Prices", were dropped from the subsequent analysis since they are statistically insignificant. 
